Emerging techniques in molecular detection of circulating tumor cells

Cho, William C.

doi:10.1586/14737159.2014.868308

Cited by 7 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 107 FA-FISH comprises a filter for detecting CTCs that have been previously enriched by blood filtration, followed by preparation of a filter spot for cells fixation and the cells analysis using the FISH assay. 108 Moreover, ALK protein expression could also be observed in CTCs isolated from lung cancer patients by immunocytochemistry. 109 FISH analysis provided sufficient positivity of EML4-ALK gene rearrangement detection from 10-1535 CTCs/mL and only required 7.5 mL of patient blood samples.…”

Section: Biomarker Analysis Of Ctcmentioning

confidence: 97%

Circulating Tumor Cell and Cell-free Circulating Tumor DNA in Lung Cancer

et al. 2016

View full text Add to dashboard Cite

Circulating tumor cells (CTCs) are tumor cells that are separated from the primary site or metastatic lesion and disseminate in blood circulation. CTCs are considered to be part of the long process of cancer metastasis. As a 'liquid biopsy', CTC molecular examination and investigation of single cancer cells create an important opportunity for providing an understanding of cancer biology and the process of metastasis. In the last decade, we have seen dramatic development in defining the role of CTCs in lung cancer in terms of diagnosis, genomic alteration determination, treatment response and, finally, prognosis prediction. The aims of this review are to understand the basic biology and to review methods of detection of CTCs that apply to the various types of solid tumor. Furthermore, we explored clinical applications, including treatment monitoring to anticipate therapy resistance as well as biomarker analysis, in the context of lung cancer. We also explored the potential use of cell-free circulating tumor DNA (ctDNA) in the genomic alteration analysis of lung cancer.

show abstract

Section: Biomarker Analysis Of Ctcmentioning

confidence: 97%

Circulating Tumor Cell and Cell-free Circulating Tumor DNA in Lung Cancer

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Techniques using antibody-target binding include immunohistochemistry approaches using either labeled fluorophores or magnetic particles with subsequent microscopy (10,149) and enzyme-linked immunosorbent assay (150). Improved high-throughput methods include protein microarrays (which have a device surface covered with capture antibodies) and mass spectrometry, both of which offer high sensitivity and specificity (151). Additionally, nanotechnology can be used to detect protein expression in CTCs through labeled nanoparticles or nanowires (116).…”

Section: Molecular Characterization Of Circulating Tumor Cellsmentioning

confidence: 99%

Circulating Tumor Cells: Fluid Surrogates of Solid Tumors

Thiele

Bethel

Králíčková

et al. 2017

Annu. Rev. Pathol. Mech. Dis.

View full text Add to dashboard Cite

Evaluation of circulating tumor cells (CTCs) has demonstrated clinical validity as a prognostic tool based on enumeration, but since the introduction of this tool to the clinic in 2004, further clinical utility and widespread adoption have been limited. However, immense efforts have been undertaken to further the understanding of the mechanisms behind the biology and kinetics of these rare cells, and progress continues toward better applicability in the clinic. This review describes recent advances within the field, with a particular focus on understanding the biological significance of CTCs, and summarizes emerging methods for identifying, isolating, and interrogating the cells that may provide technical advantages allowing for the discovery of more specific clinical applications. Included is an atlas of high-definition images of CTCs from various cancer types, including uncommon CTCs captured only by broadly inclusive nonenrichment techniques.

show abstract

“…A shotgun oncoproteomic strategy, space and time‐based, using sequential elution from immobilized metal affinity chromatography (SIMAC) and isobaric tag for relative and absolute quantitation (iTRAQ) coupled to liquid chromatography, electrospray ionization, tandem mass spectrometry (LC‐ESI‐MS/MS) is proposed to be applied in our research team by the Spanish Health System (SNS) in collaboration with international research teams to unravel signatures of ALL patients who do not respond well to treatments compared to those who do.…”

Section: Future Perspectivesmentioning

confidence: 99%

Application of oncoproteomics to aberrant signalling networks in changing the treatment paradigm in acute lymphoblastic leukaemia

Villar

Wang

Madero

et al. 2014

J Cellular Molecular Medi

View full text Add to dashboard Cite

Oncoproteomics is an important innovation in the early diagnosis, management and development of personalized treatment of acute lymphoblastic leukaemia (ALL). As inherent factors are not completely known – e.g. age or family history, radiation exposure, benzene chemical exposure, certain viral exposures such as infection with the human T-cell lymphoma/leukaemia virus-1, as well as some inherited syndromes may raise the risk of ALL – each ALL patient may modify the susceptibility of therapy. Indeed, we consider these unknown inherent factors could be explained via coupling cytogenetics plus proteomics, especially when proteins are the ones which play function within cells. Innovative proteomics to ALL therapy may help to understand the mechanism of drug resistance and toxicities, which in turn will provide some leads to improve ALL management. Most important of these are shotgun proteomic strategies to unravel ALL aberrant signalling networks. Some shotgun proteomic innovations and bioinformatic tools for ALL therapies will be discussed. As network proteins are distinctive characteristics for ALL patients, unrevealed by cytogenetics, those network proteins are currently an important source of novel therapeutic targets that emerge from shotgun proteomics. Indeed, ALL evolution can be studied for each individual patient via oncoproteomics.

show abstract

Emerging techniques in molecular detection of circulating tumor cells

Cited by 7 publications

References 25 publications

Circulating Tumor Cell and Cell-free Circulating Tumor DNA in Lung Cancer

Circulating Tumor Cell and Cell-free Circulating Tumor DNA in Lung Cancer

Circulating Tumor Cells: Fluid Surrogates of Solid Tumors

Application of oncoproteomics to aberrant signalling networks in changing the treatment paradigm in acute lymphoblastic leukaemia

Contact Info

Product

Resources

About